Genetics

Can Ocular Therapies Diversify Biogen Portfolio? - Eye On Innovation Article - Healthegy

Can Ocular Therapies Diversify Biogen Portfolio?

By Michelle Dalton | June 29, 2016

Biotechnology company Biogen (Cambridge, MA) recently committed $20 million into a collaboration with the University of Pennsylvania to co-develop gene therapies using next-generation adeno-associated virus…

Read More
OIS - Eye on Five

Eye on Five – February Edition

By Rich Kirkner | February 29, 2016

The Transcend acquisition tops the list, but February was a promising month for ophthalmology. Alcon Leaps into MIGS with Transcend With its acquisition of Transcend…

Read More
Avalanche’s Post-AMD Pivot Takes Step Outside Ophthalmology - OIS Article

Avalanche’s Post-AMD Pivot Takes Step Outside Ophthalmology

By Rich Kirkner | February 10, 2016

How far will Avalanche Biotechnologies Inc.’s pivot take it outside of ophthalmology? Following the release of disappointing topline results of its lead gene therapy candidate…

Read More
Gene Therapies Move One Step Closer to Reality

Gene Therapies Move One Step Closer to Reality

By Michelle Dalton | October 9, 2015

Positive top-line results from a pivotal Phase III study may result in the first gene therapy to win U.S. regulatory approval, and sent shares of…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.